Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, Tolerability, and PK of ART-001 in Healthy Japanese Male Volunteers
jRCT2080225277Phase 1Completed
- Sponsor
- ARTham Therapeutics, Inc.
- Start
- Jul 2020
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of ART001 (2 arms), sponsored by ARTham Therapeutics, Inc. Primary endpoints: Safety and tolerability of single and multiple doses of ART-001 and Pharmacokinetics of single and multiple doses of ART-001. Started Jul 2020; status: completed.
02
Drugs
ART001
Beyond the preview
Go deeper on jRCT2080225277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225277.